A University of Virginia study discovered 162 genes in fat tissue that differ in the way they are expressed between men and women, which could impact disease risk.
New research corroborates other studies that highlight potential associations between strong MAIT cell activation and severe COVID-19 outcomes and provide important information to help better understand the immune response to SARS-CoV-2 that could help develop new treatments.
This new data suggests that Alzheimer’s disease involves a reconfiguration of the epigenomic landscape, with the marks H3K27ac and H3K9ac affecting disease pathways by disrupting the transcription- and chromatin-gene feedback loops.
A study carried out in veterans has identified 14 new areas of genetic variation linked to risk for abdominal aortic aneurysms, which the researchers believe could help identify those at risk of experiencing these life-threatening cardiovascular events.
A large number of researchers have demonstrated that circular RNAs are correlated with the pathogenesis of various human diseases, including nervous system disorders, cardiovascular disorders, Alzheimer’s disease, diabetes, cancer, and more.
A significant number of people with severe COVID-19 carried rare genetic variants in 13 genes known to be critical in the body’s defense against influenza virus, and more than 3.5% were completely missing a functioning gene.
A study comparing the genome sequence of Alexander Fleming’s original Penicillium mold and the U.S. strain used for industrial penicillin manufacture today show the original uses slightly different mechanisms to produce penicillin, which could point to new routes for industrial production.
A detailed cellular and molecular map of the human heart has been created through a collaboration between several groups of scientists around the globe to improve understanding of its biology in both health and disease.
Researchers based at Kings College in London have discovered that commercially available antibody tests for COVID-19 vary widely in accuracy. The findings also revealed that some fast, lateral flow immunoassay tests, initially assumed to be less accurate, actually produced high quality results.
J&J’s Janssen has moved into Phase III with its single-dose COVID-19 vaccine candidate, which it plans to test in up to 60,000 study participants in eight countries, to evaluate its safety and efficacy compared with placebo.